funded by the National Natural Science Foundation of China(No.82272956).
Hepatocellular carcinoma(HCC)and biliary tract cancer(BTC)are significant health challenges in China because of their high prevalence and mortality rates.Advances in molecular diagnostics have opened new avenues for p...
supported by grants from National Key Research and Development Program of China(2017YFA0104304);National Natural Science Foundation of China(81972286 and 82073171);Natural Science Foundation of Guangdong Province(2020A1515010574 and 2020A1515010302);Guangdong Science and Technology Program(2019B020236003 and 2020B1212060019).
Liver transplantation is an effective treatment for end-stage liver disease in children,and its clinical efficacy has been validated.Split liver transplantation(SLT)can effectively expand the donor liver pool for chil...
supported by the National Natural Science Foundation of China(No.32171167);Anhui Province Educational Natural Science Project(No.2023AH040254);Tianchi Talent Introduction Plan Innovative Leader of Xinjiang Ugyur Autonomous Region(No.51052401403).
Liver cancer ranks as the sixth most common cancer globally,with hepatocellular carcinoma(HCC)accounting for approximately 75%-85%of cases.Most patients present with moderately advanced disease,while those with advanc...
supported by grants from the National Natural Science Foundation of China(82370591);Hefei Natural Science Foundation of China(2023018);Scientific Research Project of Colleges and Universities of Anhui Province(Natural Science)(2023AH040078);Anhui Medical University Research Level Improvement Program(2023xkjT010).
China is a major consumer of alcohol and tobacco.Tobacco and alcohol use are closely linked,with up to 90%of alcoholics having a history of tobacco use,and heavy smokers also tending to be alcoholics.Alcohol-related l...
Liver transplantation remains the most effective treatment for end-stage liver disease(ESLD),but it is fraught with challenges such as immunosuppression,high risk and cost,and donor shortage.In recent years,stem cell ...
the National Key Research and Development Programof China(No.2021YFA1100500);the Major Research Plan of the National Natural Science Foundation of China(No.92159202);the Key Research&Development Plan of Zhejiang Province(No.2021C03118);the National Natural Science Foundation of China(No.82303387 and No.82300742);the Natural Science Foundation of Zhejiang Province(No.LQ23H160048 and No.LQ22H160052);the Health Science&Technology Plan of Zhejiang Province(No.2022RC060);supported by the Construction Fund of Medical Key Disciplines of Hangzhou(No.OO20200093).
Background and aims:Inflammatory factors play significant roles in the development and occurrence of hepatocellular carcinoma(HCC).However,the tumor-protective functions of growth differentiation factors(GDFs)in HCC a...
supported by the grant from the Shanghai Famous Old Chinese Medicine Academic Research Studio(No.SHGZS-202246).
Background and aims:Kehuang(KH)capsule is an herbal medical product approved for the treatment of liver diseases,including liver injury,in China.However,the mechanism is still unclear.This study aimed to elucidate the...
the Natural Science Foundation of Guangdong Province(No.2017A030310252,No.2022A1515012650);the Science and Technology Program of Guangzhou(No.2024A03J0919).
Background and aims:Hepatocellular carcinoma(HCC)is a tumor of high heterogeneity and complexity,which poses significant challenges to effective treatment and patient prognosis because of its immune evasion characteri...
supported by grants from Key-Area Research and Development Program of Guangdong Province(No.2020B0101130015);Guangdong Medical Science and Technology Research Fund(No.A2021304);the Natural Science Foundation of China(No.82070611);Guangzhou Science and Technology Plan Projects(No.2023B03J1287);Guangzhou Science and Technology Program Key Projects(No.2023B01J1007);Sun Yat-Sen University Clinical Research 5010 Program(No.2020007);the Five-Year Plan of Third Affiliated Hospital of Sun Yat-sen University(No.2023W106);Clinical trial number:ClinicalTrials.gov ID:NCT03920618.
Background and aims:Antiviral therapy is essential for hepatitis B virus-related acute-on-chronic liver failure(HBV-ACLF).No data are available on the long-term prognosis or safety of tenofovir alafenamide(TAF),tenofo...